|
Company data displayed is for sample purposes only and may not reflect the most current information available on Emerging Markets Information Service (EMIS).
Pharmesis International Ltd
Main Activities: Pharmaceutical and Medicine Manufacturing
 |
Please check the full coverage of information what EMIS can offer you. | SEE SAMPLE |
Company Information |
|
Full name Pharmesis International Ltd Headquarters No.8 Yingbin Road ; Chengdu; Sichuan Legal Address 5 Kallang Sector #03-02; Singapore; Singapore; 349279 |
Status: Listed Legal Form: Public Limited Company Operational Status: Operational ISIN CODE : SG1Q12920787 Financial Auditors: Ernst & Young (2005) Incorporation Date: September 29, 2003 Total Employees: 1,097 |
|
Company Description |
| The Company is a pharmaceutical company specialising in the manufacturing of pharmaceutical products in the form of tablets, granules, pills, etc, including TCM formulated products. Additionally, its business also includes the research and development, production, sale and marketing of pharmaceutical products. |
Company Analysis |
| According to the Consolidated - Non-Audited financial statement for the first three cumulated quarters of 2012, total net operating revenues decreased with -8.21%, from CNY 47,859 thousands to CNY 43,929 thousands. Operating result decreased from CNY -9,640 thousands to CNY -13,383 thousands which means -38.83% change. The results of the period decreased -26.34% reaching CNY -11,347 thousands at the end of the period against CNY -8,981 thousands last year. Return on equity (Net income/Total equity) went from -7.13% to -10.89%, the Return On Asset (Net income / Total Asset) went from -6.82% to -10.28% and the Net Profit Margin (Net Income/Net Sales) went from -18.77% to -25.83% when compared to the same period of last year. The Debt to Equity Ratio (Total Liabilities/Equity) was 11.20% compared to 10.64% of last year. Finally, the Current Ratio (Current Assets/Current Liabilities) went from 17.97 to 13.64 when compared to the previous year. |
Key Executives |
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
Companies with Similar Main Activities |
FULL COMPANY PROFILE
|
|
2012 Y (cons) |
2012 Q3C (cons) |
|
 | ||
| Audited | Non-Audited | |
| ||
| WVB Company Financials | WVB Company Financials | |
| ||
| Unit | Thousands | Thousands |
| ||
Balance Sheet
| ||
Total Assets |
101,790 |
110,409 |
| ||
Current Assets |
74,680 |
78,295 |
| ||
Total Liabilities |
6,750 |
11,669 |
| ||
Shareholders Equity |
95,040 |
104,183 |
| ||
Current Liabilities |
6,262 |
5,738 |
| ||
| * All the accounts are in CNY. | ||
Income Statement
| ||
Total Operating Revenue |
55,252 |
43,929 |
| ||
Operational Profit (Loss) |
-22,672 |
-13,383 |
| ||
Net Profit (Loss) |
-19,439 |
-11,347 |
| ||
| * All the accounts are in CNY. | ||
Ratios
| Profitability Ratios | ||
| ||
Return on Assets (ROA) |
-19.1% |
-10.28% |
| ||
Annualised Return on Assets (ROA) |
-19.1% |
-13.71% |
| ||
Return on Equity (ROE) |
-20.45% |
-11.49% |
| ||
Annualised Return on Equity (ROE) |
-20.45% |
-15.32% |
| ||
Return on Sales (ROS) |
-35.19% |
-25.84% |
| ||
Return on Capital |
-20.45% |
-11.49% |
| ||
Gross Profit Margin |
66.78% |
59.31% |
| ||
Operating Profit Margin |
-24.41% |
-23.39% |
| Efficiency Ratios | ||
| ||
Accounts Receivable Turnover |
2.72x |
1.65x |
| ||
Inventory Turnover |
2.66x |
3.00x |
| ||
Current asset turnover |
0.74x |
0.56x |
| ||
Fixed-asset turnover |
2.04x |
1.37x |
| ||
Asset Turnover |
0.54x |
0.40x |
| Valuation figures and ratios | ||
| ||
Earning Before Interests and Taxes (EBIT) |
-22,015 |
-13,499 |
| ||
EBITDA |
-13,466 |
-10,257 |
| ||
Enterprise value |
959 |
-9,432 |
| ||
Enterprise Value / EBITDA |
-0.07 |
0.92 |
| ||
Bookvalue (BV) |
101,790 |
110,409 |
| ||
Net Cash |
19,523 |
24,567 |
| Liquidity Ratios | ||
| ||
Current Ratio |
1,192.59% |
1,364.5% |
| ||
Quick ratio |
1,082.51% |
1,260.61% |
| ||
Doom's day ratio |
411.77% |
528.15% |
| Leverage Ratios | ||
| ||
Leverage ratio |
107.1% |
111.82% |
| ||
Interest Coverage Ratio |
-78,625% |
-67,495% |
| ||
Debt to equity |
7.1% |
11.82% |
| ||
Debt to total assets |
6.63% |
10.57% |
| ||
Long Term Debt to Capital |
0.63% |
7.12% |
| Market ratios | ||
| ||
Market Capitalization/EBITDA |
-1.99 |
-1.50 |
| ||
Market Cap / Net cash |
1.37 |
0.63 |
| Trend Ratios | ||
| ||
Revenue Trend |
90.55% |
91.82% |
| ||
Net Income Trend |
113.39% |
126.34% |
| ||
Operating Income Trend |
117.58% |
142.06% |
| ||
 |